|Day Low/High||86.07 / 87.03|
|52 Wk Low/High||74.97 / 96.31|
Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea.
Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales.
Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
BTIG analyst Dane Leone noted three key reasons why he executed today's upgrade of the stock.
Bristol-Myers will conduct the study and both companies will evaluate the findings.
Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ENLC, NVS, RDI Downgrades: ATAI, PFSI, TICC, WMIH Initiations: GMRE, NGVT Read on to get TheStreet Quant Ratings' detailed report:
Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive.
Minerva Neurosciences, XBiotech and Aduro Biotech were among the biotech movers in premarket trading on Thursday.
Novartis shares edged higher after the Swiss drugmaker cautioned that pricing pressures in the U.S. and the delay of a multiple sclerosis therapy dosage would hit its generic division's sales.
Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
Stocks are narrowly mixed on Friday, putting the S&P 500 and Nasdaq at risk of snapping a six-day winning streak.
The latest earnings from two of the largest generic drug makers show how important it is for generic firms to have their own stable of higher-margin branded products.
The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.
Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.
Novartis holds a 36.5% stake in the healthcare company.
Analysts estimate total revenue will fall 6.9% to $3.53 billion in the quarter due to the loss of patent exclusivity on some drugs and divestitures of major business lines.
Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
Biotech investors should keep a close eye on the progress in this huge potential market.
Another big rally made for a day of milestones: the Dow and S&P 500 enjoyed their best back-to-back gains of the year, while the Nasdaq scored a new record.
Estimates for erenumab annual sales run as high as $2.3 billion.
Better-than-expected earnings from industry leaders including Caterpillar and McDonald's push the Dow to log triple-digit gains for the second day in a row, its best two-day stretch of the year.
A stream of positive earnings reports keep stocks on the rise on Tuesday with the Dow Jones Industrial Average logging triple-digit gains for the second day in a row.
Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid.
Novartis shares led gainers in Zurich Tuesday after the pharmaceuticals group held on to full year earnings targets and narrowly beast analysts' forecasts for first quarter earnings.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.